Mylan's Sanofi Insulin Suit Mostly Survives Dismissal Bid
By Corey Rothauser · January 27, 2026, 5:26 PM EST
A Pennsylvania federal judge Tuesday largely refused to dismiss Mylan Pharmaceuticals' antitrust lawsuit accusing Sanofi of unlawfully maintaining a monopoly in the market for injectable insulin glargine....
To view the full article, register now.